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Introduction
Evidence is strong that venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is a common complication of cancer and a manifestation of occult cancer [1] [2] [3] [4] [5] . The risk of cancer seems to be particularly high among patients with primary VTE (i.e. VTE occurring in the absence of traditional risk factors such as surgery, trauma, fracture and pregnancy) [1] .
Patients diagnosed with primary VTE have a 2-to 4-fold increased risk of a cancer diagnosis in the following year, compared with persons in the general population without VTE [2, 4] . The risk of cancer in patients with secondary VTE is controversial [3] . However, a few studies have recently indicated that VTE might be a marker for occult cancer in patients with liver disease, diabetes mellitus, inflammatory bowel disease and preexisting cancer [6] [7] [8] [9] .
The increased risk of cardiovascular mortality and diseases in patients with rheumatoid arthritis (RA), including atherosclerosis, stroke, heart failure and arrhythmia [10] [11] [12] [13] , have been recognized for many years. The increased risk can be explained by a combination of traditional cardiovascular risk factors, inflammation and immunological dysfunction [12, 14, 15] . Several studies recently have suggested that RA patients also are at increased risk of VTE [16] [17] [18] . As well, RA patients are known to have an increased risk of certain types of cancer, such as lung cancer and lymphoma, but a reduced risk of colorectal and breast cancer [19] . It remains unknown whether VTE in RA patients, which might be considered a secondary VTE, can also be a marker of occult cancer.
We therefore conducted a cohort study to examine the risk of cancer following VTE among RA patients. We compared their risk of cancer with that in an RA cohort without VTE and in a general population cohort without VTE or RA.
Methods

Setting
We conducted this study in Denmark (total population during 1978-2013 = 8 468 377 persons) using prospectively collected data from population-based medical and administrative registries. The Danish National Health Service provides tax-supported healthcare to all Danish residents, guaranteeing universal access to primary and secondary medical care.
Data sources
The Danish National Patient Registry (DNPR) [20] contains information on all inpatient hospitalizations since 1977 and on hospital outpatient and emergency room contacts since 1995. DNPR data include dates of admission and discharge, type of admission, outpatient visit dates, diagnosis codes and surgical procedures. Diagnoses were coded according to the International Classification of Diseases, Eighth Revision (ICD-8) from 1977 to 1993 and according to the Tenth Revision (ICD-10) starting in 1994. We used the DNPR to establish the study's patient cohorts.
The Danish Civil Registration System (DCRS), established in 1968, assigns a unique 10-digit personal identification number (PIN) to all Danish residents at birth or upon immigration. The PIN encodes sex and date of birth, enabling individual-level linkage across all registries [21] . The DCRS also tracks migration, place of residence and vital status. The DCRS was used for matching purposes and to establish a general population comparison cohort.
The Danish Cancer Registry (DCR) [22] contains information on all incident cancer cases since 1943 coded according to the ICD-10 (and the third version of the International Classification of Diseases for Oncology).
Study cohorts
Index cohort (RA patients with VTE) We first used the DNPR to identify all patients with a first-time inpatient or outpatient record of a primary or secondary RA diagnosis. Patients diagnosed with RA only during an emergency room visit were excluded. To be eligible for the index cohort, RA patients also had to be hospitalized or treated during an outpatient visit for VTE (primary or secondary VTE). The date of hospitalization or outpatient visit for VTE was defined as the index date. The index date of VTE had to be later than the admission date for RA. The two conditions could be diagnosed on the same day. The index date was restricted to the period from 1 January 1978 to 31 December 2013. We excluded patients with a prior or concurrent cancer diagnosis and patients with a VTE diagnosed prior to the index date. For RA and VTE diagnoses codes please see Appendix 1.
RA comparison cohort without VTE For each patient included in the index cohort, we randomly selected up to five matched patients with a first-time diagnosis of RA during the period 6 months before to 6 months after the RA diagnosis date of a patient in the index cohort. RA patients with VTE from the index cohort and the matched RA patients without VTE are assigned the same index date, which corresponds to the VTE date of the index cohort member. The interval between the RA diagnosis date and the index date of members of the RA comparison cohort without VTE had to be the same length as the interval between the RA diagnosis date and index date of the corresponding member of the index cohort.
Persons from the RA comparison cohort without VTE had to be alive on their index date, without a VTE or cancer diagnosis prior to the index date. Matching by year of birth and sex was carried out with replacement. We identified 379 RA comparison cohort members who received a VTE diagnosis after the index date of the index cohort member (which is the date of their VTE). In the analyses, these patients were censored on their VTE diagnosis date.
General population comparison cohort For each patient included in the index cohort, we identified five matched patients from the general population who were alive on the index date (VTE date of the index cohort member) and were not hospitalized or treated during an outpatient visit for RA, VTE or cancer on or before the index date. Matching by year of birth and sex occurred on the index date.
Cancer outcomes
We obtained information on cancer diagnosed after the index date from the DCR [22] . Cancer outcomes were defined as cancer overall and as specific cancer types. We grouped the cancers as in the cancer report published by the Danish National Board of Health [23] .
Covariates
The analysis included covariates such as gender, age categories (≤ 50, > 50-70 and 70+ years), calendar year of the index date (categorized into two periods, 1978-1993 and 1994-2013 ) and prior surgical procedures. A prior surgical procedure was defined as any procedure registered in the DNPR during the 3 months preceding the index date.
Statistical analyses
All individuals were followed from the index date until a cancer diagnosis, death, emigration or 31 December 2013, whichever came first. We censored comparison cohort members if they were diagnosed with a VTE or RA during the follow-up period.
We tabulated characteristics of the study populations, including age, gender and calendar year of the index date. We computed the cumulative incidence of cancer with 95% confidence intervals (CIs) during the total follow-up period, as well as 0-1 year and +1 year following the index date, using the cumulative incidence method and considering death as a competing risk [24] .
We calculated incidence rates (IRs) of cancer for the three cohorts, expressed as IRs per 1000 person-years (p-y) of follow-up. We used Cox regression analysis to calculate hazard ratios. Because the hazard ratio is a measure of the incidence rate ratio (IRR), as a result of the study design, we used the term IRR instead of hazard ratio, with 95% CIs, comparing the cancer risk in the index cohort with the cancer risk in the two matched comparison cohorts. IRRs were calculated overall for any cancer and for selected cancer types. The analyses were performed for the entire follow-up time after the index date, as well as for 0-1 year and +1 year after the index date (maximum 36 years). The proportional hazard assumption was evaluated graphically, using log-log plots and with the Schoenfeld method using residuals, and found to be fulfilled for all three periods. We also stratified the analyses by the time interval between RA and VTE diagnoses using two categories: VTE within 1 year after RA diagnosis and VTE more than 1 year after RA diagnosis.
In order to study potential differences in the association between VTE and cancer in subgroups of patients, we stratified all analyses by gender, age groups and calendar-year periods of the index date, keeping the matching intact. We also stratified the analysis by presence/absence of surgery within 3 months preceding the index date (defined as RA-related surgery if it was a joint or soft tissue procedure, and not related to RA if it was another procedure); here we dissolved the matching and adjusted for gender, age and calendar year when appropriate.
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Description of the study population
We identified 2546 RA patients with VTE, 2497 of whom we were able to match with members of both comparison cohorts. The 2497 RA patients with VTE constituted the index cohort. We also identified 11 672 RA patients in the comparison cohort without VTE, and 12 730 persons in the general population comparison cohort. Table 1 provides characteristics of the three cohorts. They had similar distributions of gender, age and year of index date, corresponding to successful matching. The rate of a surgical procedure within 3 months before the index date was 16.9% in the index cohort, compared with 6.4% in the RA comparison cohort without VTE and 3.0% in the general population comparison cohort. The majority of patients included in the index cohort experienced a VTE event > 1 year after their RA diagnosis.
Cancer risk
The cumulative incidence of cancer within the first year following the index date was 3.2% (95% CI, 2.5-3.9) in the index cohort (RA with VTE), 2.2% (95% CI, 2.0-2.5) in the RA comparison cohort without VTE, and 2.0% (95% CI, 1.7-2.2) in the general population comparison cohort. The incidence rate of cancer during this follow-up period was 40.0 per 1000 p-y (95% CI, 31.2-48.9 per 1000 p-y) in the index cohort, compared with 23. 
Stratified analyses
In the index cohort, the IRR for cancer was increased in both men and women within the first year following the index date (VTE diagnosis date), as well as in the period from > 1 to 36 years following the index date. Similar findings were observed for all age groups. When VTE was diagnosed within 1 year of the RA diagnosis, we observed no increased cancer risk within the first year following the index date, but an association was observed for cancer risk from > 1 to 36 years following the index date. If VTE was diagnosed more than 1 year after an RA diagnosis, an increased risk of cancer was observed throughout the follow-up period (Table 3) . Risk of cancer was increased in RA patients with VTE regardless of the index calendar year. It was also increased in RA patients with VTE and without previous surgery within 3 months before the index date (Table 3) . In RA patients with VTE, joint procedures accounted for 31% and soft tissue procedures for 6% of all previous procedures. In RA patients without VTE and the general population the corresponding numbers were 18% and 8%, and 13% and 3%, respectively. Procedures not related to RA accounted for 28%, 11% and 5% of all previous procedures in RA patients with VTE, RA patients without VTE and the general population, respectively.
Risk of selected cancer types
During the first year after the index date, we observed an increased IRR in RA patients with VTE compared with the RA cohort without VTE for lung cancer (IRR, 2.06; 95% CI, 1.09-3.89), with corresponding cumulative incidences of 0.6% vs. 0.4% and corresponding incidence rates of 7.2 (95% CI, 3.4-11.0) vs. 3.8 (95% CI, 2.6-4.9) per 1000 p-y. RA patients with VTE also had an 
Discussion
In this population-based cohort study of 2497 RA patients with VTE, we observed a 1.8-fold increased risk of any cancer compared with the RA cohort without VTE, and a 2.1-fold increased risk of any cancer compared with the general population cohort within the first year following a VTE diagnosis. In the following years, the risk of any cancer decreased slightly, but remained elevated at 16% to 36%. Thus, VTE in RA patients might be a marker of occult cancer.
Previous studies have shown that RA patients are at increased risk of VTE [16] [17] [18] and that RA patients also are at increased risk of certain types of cancer [19] . To the best of our knowledge, this is the first study to identify VTE as a possible independent marker of cancer in RA patients.
The increased risk of cancer we observed within the first year following a VTE diagnosis was similar to that found in previous studies of patients with primary VTE [2, 4] and in patients with secondary VTE [6] [7] [8] . The increased short-term risk of cancer might be explained by heightened diagnostic workup if RA patients with VTE were more likely to be examined for cancer during a hospital stay prompted by VTE. However, more VTE patients now are treated during outpatient visits and the effect of detection bias is diminishing. Cancer screening would most likely result in identification of cancer at an early stage. However, Sørensen et al. [4] showed that 40% of patients diagnosed with cancer within 1 year after hospitalization for thromboembolism already had distant metastases. This suggests that VTE is a consequence of undetected cancer, rather than the cause of cancer. Lung cancer patients belonged to the group of cancers with the highest incidence rates of VTE [25] , and thus, it is not surprising that the strongest association between VTE and cancer was found for lung cancer. The increased risk of cancer beyond the first year of VTE found in our study is consistent with the findings of some [2, 26] , but not all, studies [4] of patients with primary VTE, as well as some [7] , but not all, studies of patients with secondary VTE [6, 8] . The long-term association between VTE and cancer in RA patients might be a result of common physiological factors associated with both thrombosis and initiation of carcinogenesis, including activation of fibrinolysis, increased levels of prostaglandins and smoking [27] [28] [29] [30] . Treatment of RA may influence the risk of cancer. The evidence supporting the effectiveness of aspirin, used as a painkiller in RA patients to some extent, for prevention of cancer, in particular colorectal cancer, is substantial [31] . However, the evidence of a reduced risk of lung cancer [32] and breast cancer [33] associated with aspirin use is not compelling. Methotrexate, the most common treatment for RA, has been linked to increased risk of some cancers compared with other available drug treatment options in RA patients [34] , but reduced risk of cardiovascular events [14] . RA patients undergo a number of surgical procedures during their lifetime, including both major procedures and soft tissue procedures [35] , increasing the risk of VTE in these patients and the risk of identifying occult cancer.
As this is an observational study, we are unable to make a causal link between the occurrence of VTE and cancer. Our finding of a clear association of VTE with cancer when a VTE occurred more than 1 year after diagnosis of RA and a less clear association if the time interval between RA and VTE diagnosis was less than 1 year, introduces further uncertainty about the appropriate time for searching for occult cancer in RA patients with VTE. The benefits of screening for cancer, including early diagnosis and improved prognosis, among RA patients with VTE need to be weighed against risks associated with routine screening, such as financial cost, need for confirmatory tests, anxiety, psychological stress and fear of future tests. No studies to date have shown any clinically significant benefit of extensive routine screening, including scanning of the abdomen and pelvis, or laboratory and other radiological investigations [36] [37] [38] . However, a limited screening strategy, including history taking, physical examination, basic blood testing, chest radiography and age-specific and sex-specific cancer screening may be adequate for patients who have a first unprovoked VTE [36] . Our finding of no association between VTE and cancer in the people with previous surgery might be one additional criterion to judge the benefit of screening. Our observation that RA patients with VTE had twice as many major joint procedures and three times as many procedures not related to RA, including also major abdominal procedures, compared with RA patients without VTE and the general population suggests that surgery is a strong intermittent risk factor for VTE. Thus, type of surgery before VTE cannot be used to select patients for screening.
Our study's strengths and limitations are common to many registry studies. The validity of our findings is dependent on the accuracy of registry data. The validity of VTE diagnoses in the DNPR has been confirmed in 75% to 95% of patients [39] and the validity of the VTE diagnosis is most likely independent of RA status. The validity of RA diagnoses in the DNPR is likely to be high because RA is diagnosed and treated by specialists in rheumatology. This is supported by previous findings of a positive predictive value of 98% for DNPR diagnoses of connective tissue diseases in general, including RA [40] . To our knowledge, no validation study on RA diagnoses in the DNPR has been published previously. A recent study of the Swedish National Patient Registry showed that RA diagnoses could be verified in 83% of patients using a base-case definition of RA (first visit to a rheumatologist regarding a diagnosis of RA) and in 91% of patients using a strict definition of RA (two visits to a rheumatologist regarding RA within a year of the first visit and no disease-modifying anti-rheumatic drugs more than 6 months before the first visit for RA) [41] . The majority of patients with a non-confirmed diagnosis of RA had other inflammatory rheumatic diseases [41] . Because we defined RA using only the first diagnosis of RA in the DNPR, we have introduced misclassification of RA patients; thus some of our RA patients might not have RA but another rheumatic disease. However, it is hard to believe that this misclassification is dependent on a later VTE or cancer status. The completeness and positive predictive value of cancer diagnoses in the DCR has been shown to be as high as 95-98% when validated against medical records [42, 43] . Nevertheless, the validity of these diagnoses could have changed during 1978-2013, with more cancer events identified with improved diagnostic tools over time. However, this applies to RA patients with VTE as well as the two comparison cohorts. We lack information on smoking history, as well as specific information about the level of autoantibodies, RA disease activity and RA treatment history, in addition to body mass index and hormonal therapy. Because these factors have previously been found to be associated with RA, VTE or cancer, unmeasured confounding as a result of these factors could affect our associations, particularly those for lung cancer.
In conclusion, among RA patients, VTE may not only result from inflammation and immunological dysfunctions associated with RA disease. VTE might also be a marker for occult cancer, analogous to findings for patients with primary VTE without underlying RA. However, we see no role for extensive screening for occult cancer in RA patients who develop VTE.
